Mallinckrodt Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MALLINCKRODT, and what generic alternatives to MALLINCKRODT drugs are available?
MALLINCKRODT has forty-six approved drugs.
There are thirty-five US patents protecting MALLINCKRODT drugs.
There are one hundred and sixty-five patent family members on MALLINCKRODT drugs in twenty-three countries and seventy-eight supplementary protection certificates in eight countries.
Summary for Mallinckrodt
| International Patents: | 165 |
| US Patents: | 35 |
| Tradenames: | 40 |
| Ingredients: | 29 |
| NDAs: | 46 |
| Patent Litigation for Mallinckrodt: | See patent lawsuits for Mallinckrodt |
| PTAB Cases with Mallinckrodt as patent owner: | See PTAB cases with Mallinckrodt as patent owner |
Drugs and US Patents for Mallinckrodt
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | TRIAD | acetaminophen; butalbital; caffeine | CAPSULE;ORAL | 089023-001 | Jun 19, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | AA | RX | Yes | Yes | 8,573,210*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Mallinckrodt | PEMOLINE | pemoline | TABLET;ORAL | 075726-003 | Mar 30, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Mallinckrodt Inc | BAROS | sodium bicarbonate; tartaric acid | GRANULE, EFFERVESCENT;ORAL | 018509-001 | Aug 7, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Mallinckrodt | OXYCODONE AND ACETAMINOPHEN | acetaminophen; oxycodone hydrochloride | TABLET;ORAL | 040550-002 | Jun 30, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mallinckrodt
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | 4,999,375 | ⤷ Sign Up |
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | 5,873,359*PED | ⤷ Sign Up |
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | 5,485,827*PED | ⤷ Sign Up |
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | 5,036,102 | ⤷ Sign Up |
| Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | 6,028,222*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Inhalation | 100 ppm and 800 ppm | ➤ Subscribe | 2014-05-20 |
| ➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
| ➤ Subscribe | Injection | 1000 mg/100 mL (10 mg/mL) | ➤ Subscribe | 2011-04-07 |
Premature patent expirations for MALLINCKRODT
International Patents for Mallinckrodt Drugs
Supplementary Protection Certificates for Mallinckrodt Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 2465580 | SPC/GB21/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1175904 | 2007C/048 | Belgium | ⤷ Sign Up | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
| 2932970 | 1890039-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
